Article

Generated by MedBot Healthcare AI Assistant

Date: August 29, 2025

End of Document
End of Document
Recent advances and challenges of cellular immunotherapies in lung cancer treatment. Authors: Yang C, Liu Y, Huang Z, Liu S, Zhang X, Liu Q, Dai J. Journal: Exp Hematol Oncol (2025) Abstract No abstract available. Background Lung cancer is a common malignant tumor with high morbidity and fatality rates in both male and female [1 , 2]. According to the latest global cancer burden research from the World Health Organization (WHO) in 2024, there were approximately 2.48 million new cases of lung cancer, representing approximately one-eighth of all cancer cases [3 , 4]. The number of deaths caused by lung cancer reached up to 1.82 million, accounting for 18.7% of all cancer deaths worldwide, making lung cancer the leading cause of cancer deaths [3]. The two major types of lung cancer are small cell carcinoma (SCLC) and non-small cell carcinoma (NSCLC). NSCLC accounts for approximately 85% of all diagnosed lung cancers [2 , 5 , 6]. For many years, the main treatment strategy for lung
End of Document
End of Document

End of Document		
End of Document		
End of Boodinent		

End of Document

Generated on August 29, 2025 by MedBot Healthcare Al Assistant Professional Medical Research Analysis & Insights

> Document Version: 1.0 Generated at: 10:22:41

••••••